Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids

authors:

avatar Sosa-HenrIquez Manuel 1 , * , avatar Gomez de Tejada-Romero Maria Jesus 2 , avatar Saavedra-Santana Pedro 2 , avatar Blazquez-Cabrera Jose Antonio 2 , avatar Garcia-Vadillo Jess Alberto 2 , avatar Valdes-Llorca Carmen 2 , avatar Diaz-Curiel Manuel 2 , avatar Munoz-Torres Manuel 2 , avatar Martinez-Rodriguez Maria Elena 2 , avatar Navarro-Ceballos Carmen 2 , avatar Sanfelix-Genoves Jose 2 , avatar Cancelo-Hidalgo Maria Jesus 2 , avatar Carpintero-Benitez Pedro 2 , avatar Mesa-Ramos Manuel 2 , avatar Palacios-Gil Antunano 3

Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), Spain
Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), msosa@ono.com, Spain
Santiago, International Society of Osteoporosis and Bone Mineral Metabolism (SIBOMM), Madrid

how to cite: Manuel S, Jesus G D T M, Pedro S, Jose Antonio B, Alberto G J, et al. Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids. Int J Endocrinol Metab. 2012;10(2): 480-485. https://doi.org/10.5812/ijem.3442.

Abstract

Background:

Glucocorticoids taken orally increase the risk of fractures. It has been noted that a dose as low as 2.5 mg/day increases the risk of vertebral fracture. What is less clear is the possible influence of other risk factors for osteoporosis on the presence of non-vertebral fractures in patients taking glucocorticoids.

Objectives:

A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.

Patients and Methods:

A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.

Results:

28.3% of the patients who were taking glucocorticoids at a daily oral dose of 7.5 mg/day for a minimum of 3 months had suffered at least one non-vertebral fracture. The risk increased with age, the number of months the glucocorticoids had been taken, the presence of falls in the last year and, above all, with a maternal history of hip fracture.

Conclusions:

In patients taking oral glucocorticoids for over 3 months at doses higher than 7.5 mg/day of prednisone or equivalent, the prevalence of non-vertebral fractures was 28.3%. Some risk factors associated with the presence of these fractures were identified. The duration of glucocorticoid use appears to be more strongly related to the presence of non-vertebral fractures than the daily dose.

Full Text

Full text is available in PDF